Connecticut
Psilocybin has mixed legal status in Connecticut as of 17 Aug 2026.1
- Status changed at this review, and checked against 2 cited sources at this review.
1. What the law is
Public Act 26-108 (SB 191), signed by Gov. Lamont June 4, 2026, effective July 1, 2026: repeals and replaces C.G.S. section 17a-484g to expand and extend the psychedelic-assisted therapy pilot program: administered by a medical school in the state under an FDA-approved research program, opens eligibility from veterans/first responders to any adult 18+ meeting IRB clinical criteria, removes the sunset tied to federal rescheduling. Builds on SB 1083 (2021, study) and HB 5506 (2022, pilot funding).1
Connecticut runs a psilocybin pilot, open to adults 18 and older who enroll in an FDA-approved research program administered by a medical school in the state. Public Act 26-108, the enacted form of Senate Bill 191, was signed June 4, 2026 and took effect July 1, 2026. Outside the pilot, possession is still a criminal offense. A 2025 bill to decriminalize possession of up to half an ounce, HB 7065, passed the House and died in the Senate.
Connecticut's scheduling is done by regulation rather than by a list in the statute: the Commissioner of Consumer Protection maintains the schedules under Connecticut General Statutes (CGS) Sec. 21a-243, and psilocybin sits in Schedule I there. Possession, sale and manufacture are criminal offenses. One carve-out exists, and it is a state-run psychedelic-assisted therapy pilot. Public Act 26-108, the enacted form of Senate Bill 191, was signed by Governor Lamont on June 4, 2026 and opened that pilot to adults 18 and older taking part in an FDA-approved research program administered by a state medical school. Step outside it and the criminal penalties apply.
Connecticut classifies psilocybin as a Schedule I hallucinogen through regulations issued under CGS Sec. 21a-243, the statute directing the Commissioner of Consumer Protection to maintain the state's controlled-substance schedules. The legislature has acted on psychedelics through study and pilot programs. Senate Bill 1083 (2021) directed a study of psychedelic-assisted therapy; House Bill 5506 (2022) funded a pilot program; and Public Act 26-108 (Senate Bill 191, 2026) expanded that pilot by opening eligibility beyond veterans and first responders to any adult 18 or older meeting institutional review board clinical criteria, requiring administration by a state medical school under an FDA-approved research program, and removing the program's prior sunset tied to federal rescheduling. A separate 2025 measure, House Bill 7065, would have made possession of up to half an ounce of psilocybin a civil rather than criminal matter; it passed the House but died on the Senate calendar at adjournment, so it never took effect. Connecticut is therefore not a decriminalized jurisdiction: outside the medical-school pilot, psilocybin remains a controlled substance and possession remains a criminal offense.
2. Pending legislation
Introduced but not yet law. If a bill passes, this record changes with it.
Two bills are recorded for Connecticut. SB 00191 of 2026, which expanded the psychedelic-assisted therapy pilot, is now Public Act 26-108. The other is HB 5456 of 2025.
3. History
The laws behind today’s status, when each took effect, and every review since, in order.
Senate Bill 1083 directs a state study of psychedelic-assisted therapy.
House Bill 5506 establishes and funds a psychedelic-assisted therapy pilot program.
House Bill 7065 is tabled on the Senate calendar and dies at adjournment; possession remains a criminal offense.
House Bill 7065, which would treat possession of up to half an ounce of psilocybin as a civil infraction, passes the House 74-65.
Senate passes Senate Bill 191 (35-0) to expand the psychedelic-assisted therapy pilot program.
House passes Senate Bill 191 (122-27).
Governor Lamont signs Senate Bill 191 as Public Act 26-108, expanding pilot eligibility to adults 18 and older under an FDA-approved research program.
Connecticut widened its psilocybin pilot: a law signed on 4 June 2026 opened it beyond veterans and first responders to adults generally. A separate 2025 bill to decriminalize possession passed the House and died in the Senate.
Mixed status takes effect.
Connecticut's expanded pilot program took effect on 1 July 2026, not on the June signing date the entry previously showed. Corrected from the text of the act.
Connecticut's entry now cites the text of the act itself rather than a bill tracking page that never mentioned psilocybin. Nothing about the law changed; the citation now supports what the entry says.
4. Trials in Connecticut
Interventional psilocybin trials with at least one study site in Connecticut, drawn from ClinicalTrials.gov, EU CTIS, and ISRCTN. Registry data is reported by sponsors and shown as filed.
Recruiting, active, completed and closed add up to the 20 trials with a study site in Connecticut, as of Aug 2026. Closed covers trials terminated, suspended, withdrawn or left unverified.
| Registry ID | Trial | Phase | Sponsor | Status | Started |
|---|---|---|---|---|---|
| NCT07306364 (opens in new tab) | Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain (opens in new tab)Site at Connecticut Mental Health Center, New Haven | Phase Phase 2 | Sponsor Yale University | Status Not yet recruiting | Started |
| NCT07693153 (opens in new tab) | The Effects of Psilocybin on Social Connectedness (opens in new tab)Site at Connecticut Mental Health Center, New Haven | Phase Phase 1 | Sponsor Yale University | Status Not yet recruiting | Started |
| NCT07449351 (opens in new tab) | Psilocybin Microdosing on Cognition, Mood and Quality of Life (opens in new tab)Site at Olin Neuropsychiatry Research Center, Hartford | Phase Phase Early 1 | Sponsor Yale University | Status Not yet recruiting | Started |
| NCT07118332 (opens in new tab) | Psilocybin as a Treatment for Chronic Pain in Smokers (opens in new tab)Recruiting at Department of Veterans Affairs, West Haven | Phase Phase Early 1 | Sponsor Yale University | Status Recruiting | Started |
| NCT07610369 (opens in new tab) | The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease (opens in new tab)Recruiting at Yale University, New Haven | Phase Phase 2 | Sponsor Yale University | Status Recruiting | Started |
| NCT06793397 (opens in new tab) | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Recruiting at Yale School of Medicine - Yale Program for Psychedelic Science, New Haven | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Recruiting | Started |
| NCT06160284 (opens in new tab) | Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) (opens in new tab)Recruiting at Yale University, New Haven | Phase Phase 1 | Sponsor Yale University | Status Recruiting | Started |
| NCT06464367 (opens in new tab) | Mechanistic Studies of Psilocybin in Headache Disorders (opens in new tab)Recruiting at VA Connecticut Healthcare System, West Haven | Phase Phase Early 1 | Sponsor Yale University | Status Recruiting | Started |
| NCT06442423 (opens in new tab) | Open-Label Psilocybin Study in Transdiagnostic Population (opens in new tab)Recruiting at Connecticut Mental Health Center - Yale School of Medicine, New Haven | Phase Phase 1 | Sponsor Yale University | Status Recruiting | Started |
| NCT06624137 (opens in new tab) | Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics (opens in new tab)Sites in Hamden and West Haven | Phase Not stated | Sponsor Yale University | Status Terminated | Started |
| NCT06308653 (opens in new tab) | Psilocybin for Major Depressive Disorder (MDD) (opens in new tab)Site at Connecticut Mental Health Center, Yale University, New Haven | Phase Phase 3 | Sponsor Usona Institute | Status Active, not recruiting | Started |
| NCT05370911 (opens in new tab) | Effects of Repeated Psilocybin Dosing in OCD (opens in new tab)two sites in New Haven | Phase Phase 1 | Sponsor Yale University | Status Active, not recruiting | Started |
ClinicalTrials.gov data courtesy of the U.S. National Library of Medicine.
8 more trials on file for Connecticut.
The table above lists the first 12, recruiting first. The register opens on all 20 and narrows further by condition, status, and stage.
See all 20 Connecticut trials in the register
Condition Depression - Major Depressive Disorder (2) · Major Depressive Disorder (MDD) (2) · Migraine Headache (2) · Obsessive-Compulsive Disorder (2) · Depressive Disorder, Major (2)
Phase Phase 1 (13) · Phase 2 (3) · Phase 3 (3) Status Recruiting (6) · Completed (6) · Active, not recruiting (3)
Registry records remain public on ClinicalTrials.gov and EU CTIS.
5. Common questions
Is psilocybin legal in Connecticut?
No. Psilocybin is a Schedule I controlled substance under Connecticut's controlled substance scheduling regulations issued pursuant to CGS Sec. 21a-243. Possession, sale, and manufacture are criminal offenses, except for participation in the state's FDA-approved psychedelic-assisted therapy pilot program.
Is psilocybin decriminalized in Connecticut?
No. House Bill 7065 (2025) would have reduced possession of up to half an ounce of psilocybin to a civil infraction, but it passed only the House and died on the Senate calendar at adjournment. Possession of psilocybin remains a criminal offense in Connecticut.
What does Public Act 26-108 (Senate Bill 191) do?
Public Act 26-108, signed June 4, 2026, expands and extends Connecticut's psychedelic-assisted therapy pilot program. The act opens eligibility from veterans and first responders to any adult 18 or older who meets institutional review board clinical criteria, requires the program to be administered by a state medical school under an FDA-approved research program, and removes the prior sunset tied to federal rescheduling. It does not legalize psilocybin for the general public.
Can the public legally use psilocybin under the Connecticut pilot program?
Only as authorized by the act. Public Act 26-108 permits supervised participation by adults 18 and older who meet institutional review board clinical criteria within an FDA-approved research program administered by a state medical school. It is not a general-access or commercial legalization framework, and use outside the pilot remains unlawful under CGS Sec. 21a-243.
Are magic mushrooms ("shrooms") legal in Connecticut?
"Magic mushrooms" and "shrooms" are common names for fungi that contain psilocybin. Psilocybin has mixed legal status in Connecticut as of 17 Aug 2026. Some laws control the compound and the fungus separately, so this record states the position for psilocybin in Connecticut.
Sources and confidence
Every status line is checked against the primary sources below. How each record is graded for confidence is set out in the methodology.
- 1.cga.ct.gov (opens in new tab) · cga.ct.gov
- 2.cga.ct.gov (opens in new tab) · cga.ct.gov
Cited at the review
This information is for educational purposes only and does not constitute legal advice. Laws change frequently, and enforcement practice can differ from the letter of the law. Verify current status with local authorities before relying on this record.
Changes to this record
Every change we have made to this record, dated, corrections included. Nothing changes silently.
Connecticut's entry now cites the text of the act itself rather than a bill tracking page that never mentioned psilocybin. Nothing about the law changed; the citation now supports what the entry says.
Connecticut's expanded pilot program took effect on 1 July 2026, not on the June signing date the entry previously showed. Corrected from the text of the act.
Connecticut widened its psilocybin pilot: a law signed on 4 June 2026 opened it beyond veterans and first responders to adults generally. A separate 2025 bill to decriminalize possession passed the House and died in the Senate.
Connecticut: psilocybin legal status. The Psilocybin Record. Accession US-CT-001. Status as of 17 Aug 2026. https://psilocybinlegalization.com/record/connecticut
If this record changes, know first.
One email when Connecticut's status changes.
No spam. Never shared. Unsubscribe anytime. Privacy statement